Consideration of a platform for managing the distribution of specialty pharmaceuticals
First written in FY2019. 3 of 4 entries say "Advanced", first in FY2021-Q3. Latest entry: FY2022-Q3.
1 other company's latest entry also says "Advanced".
- FY2022-Q3AdvancedAnnual report
「In November 2021, Alfresa announced a joint research project with Tokyo Medical and Dental University on the personalized medicine support platform “NOVUMN.” The project involves linking data from the electronic medical records system at Tokyo Medical and Dental University Hospital, manufactured by Fujitsu Japan Corporation, with “NOVUMN,” with the aim of expanding “NOVUMN” functionality and improving convenience and operational efficiency at medical institutions.」
Following pilot operations and the provision of commercial services, NOVUMN advanced to the collaborative research stage, with data integration being pursued with the electronic medical record system of Tokyo Medical and Dental University Hospital. - FY2021AdvancedAnnual report
「In November 2020, アルフレッサ jointly developed the personalized medicine support platform NOVUMN with PHC株式会社 and Fujitsu Japan Limited, using RFID, cloud-based infrastructure and IoT technology, and began providing commercial services to medical institutions.」
The specialty-pharmaceutical distribution management platform advanced from pilot operations to the launch of NOVUMN commercial services for medical institutions. - FY2021-Q3AdvancedAnnual report
「In November 2020, as part of its efforts to support personalized medicine for specialty pharmaceuticals, Alfresa began pilot operations of NOVUMN (ノヴァム), a personalized medicine support platform, with PHC Corporation (head office: Minato-ku, Tokyo) and Fujitsu Japan Limited (head office: Minato-ku, Tokyo).」
The specialty-pharmaceutical distribution management platform using RFID, IoT and other technologies advanced from the development-planning stage to the pilot-operation stage for NOVUMN. - FY2019First statedAnnual report
「In March 2019, the company entered into a basic agreement with PHC Corporation and Fujitsu FIP Corporation to consider developing a new platform using IoT technologies such as RFID and cloud computing to manage the distribution of specialty pharmaceuticals.」
The company began considering the development of a platform for managing the distribution of specialty pharmaceuticals using RFID, cloud computing and other technologies with PHC and Fujitsu FIP.